COX-2 class reunion? Prexige, Arcoxia inch forward
This article was originally published in Pharmaceutical Approvals Monthly
Merck's resubmitted NDA for Arcoxia (etoricoxib) seeks a narrowed indication for treatment of osteoarthritis only; the original NDA for the follow-on to Merck's now-withdrawn Vioxx, submitted in 2003, sought uses in OA, RA, chronic low-back pain, acute pain, dysmenorrhea, gouty arthritis and ankylosing spondylitis. Merck anticipates a six-month review, with a user fee goal at the end of April 2007. Novartis plans to resubmit its COX-2 inhibitor Prexige (lumiracoxib) in the first half of 2007; the NDA has been "not approvable" since 2003. On Nov. 7, Novartis announced approval of Prexige for osteoarthritis in the European Union and Canada...
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.